Disease relevance of Ro 13-8996

• In plantar-type tinea pedis caused primarily by T rubrum, once-daily oxiconazole cream resulted in a mycologic cure in 76% of patients [1].
• In comparative clinical trials of various types of dermatophytoses, oxiconazole was shown to be as effective as or more effective than miconazole, clotrimazole, and tolnaftate creams, and as effective as econazole and bifonazole creams [1].
• Although both antifungal drugs showed a large inhibitory effect on C. albicans, oxiconazole had a very low inhibitory effect on Lactobacillus isolates [2].
• Fifty-one women with vaginal candidiasis were included in an open randomized study to compare the efficacy and local tolerance of a single-dose treatment with 600 mg oxiconazole (one vaginal tablet) with that of a 3-day treatment with econazole (one 150 mg ovule daily) [3].
• Toxicity of intravitreal oxiconazole [4].

High impact information on Ro 13-8996

• Influence of growth phase on the susceptibility of Candida albicans to butoconazole, oxiconazole, and sulconazole [5].
• Applied once daily for four weeks in the treatment of tinea pedis or for two weeks in the treatment of tinea corporis, tinea cruris, and tinea versicolor, 1% oxiconazole cream has produced mycologic and clinical cures in at least 80% of patients [1].
• However, differences between results for oxiconazole and econazole and the dermatophytes were only marginal [6].
• Further in vitro studies with oxiconazole nitrate [6].
• 128 isolates of pathogenic fungi were tested in vitro against oxiconazole, miconazole, and ketoconazole using an agar dilution method [7].

Chemical compound and disease context of Ro 13-8996

• In the management of tinea pedis, a cost analysis suggested that initial therapy with terbinafine 1% cream was more costly than initial therapy with miconazole, oxiconazole or clotrimazole [8].
• Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis [9].
• The inhibitory effect of isoconazole and oxiconazole in 0.2, 0.1 and 0.05 microg/ml concentrations on 58 Lactobacillus spp. and Candida albicans (AJD 180) were investigated, using an agar diffusion method [2].
• The new imidazole derivative Z-[2,4-dichloro-2-imidazol-1-yl)acetophenone]-O-(2,4-dichlorobenzyl)-oxime nitrate (oxiconazole, Ro 13-8996) is characterized by a broad fungistatic spectrum against the agents of human mycoses in vitro [10].

Biological context of Ro 13-8996

• Synthesis of DNA was inhibited by subinhibitory concentrations of oxiconazole in parallel to cell multiplication, whereas synthesis of RNA, protein and carbohydrate was decreased to a lesser extent [10].

Associations of Ro 13-8996 with other chemical compounds

• In vitro some antimycotics (amphotericin B,5-fluorocytosine, oxiconazole, amorolfine and ketoconazole) were tested against A. fumigatus by agar dilution method [11].
• Some benzyloxyimio compounds, related to oxiconazole and having a 1H-indole or 1H-benzimidazole moiety, have been synthesized and tested in vitro for their antimycotic activity against Candida tropicalis and C. albicans [12].

Analytical, diagnostic and therapeutic context of Ro 13-8996

• The assay was sensitive enough to measure precisely the small amounts of unchanged compound in plasma after intravaginal application of labelled oxiconazole to human volunteers [13].
• The method was applied to 13-week tolerance studies in dogs and rats in order to follow oxiconazole concentrations in plasma after oral administration of the compound [13].
• Clinical and experimental mycotic keratitis caused by Aspergillus terreus and the effect of subconjunctival oxiconazole treatment in the animal model [14].

References